Brookstone Capital Management Purchases 3,098 Shares of Amgen Inc. $AMGN

Brookstone Capital Management lifted its position in Amgen Inc. (NASDAQ:AMGN) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 74,409 shares of the medical research company’s stock after buying an additional 3,098 shares during the quarter. Brookstone Capital Management’s holdings in Amgen were worth $24,355,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. increased its stake in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the period. Grantham Mayo Van Otterloo & Co. LLC increased its stake in shares of Amgen by 12.8% in the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 4,245 shares of the medical research company’s stock worth $1,185,000 after purchasing an additional 481 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Amgen by 4.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 55,239 shares of the medical research company’s stock worth $15,423,000 after purchasing an additional 2,344 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently weighed in on AMGN shares. Argus increased their target price on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Leerink Partners reiterated a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Mizuho increased their price objective on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. HSBC restated a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Finally, Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Trading Up 0.1%

Amgen stock opened at $349.00 on Tuesday. The business has a 50 day moving average price of $362.96 and a two-hundred day moving average price of $331.05. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The stock has a market cap of $188.14 billion, a price-to-earnings ratio of 24.53, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.